跳至主要内容
临床试验/ITMCTR2200006581
ITMCTR2200006581尚未招募未知

Study to Evaluate the Effect of Shumu Liujunzi Decoction combined with Endoscopic Treatment on the Quality of Life and Clinical Outcomes in Patients with Type 1 Gastric Neuroendocrine Tu

China-Japan Friendship Hospital0 个研究点开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 —(—)
性别
All

入选标准

  • (1)Age = 18 years old
  • (2)According to the WHO (5th) classification and grading standards for gastrointestinal / hepatobiliary pancreatic neuroendocrine tumors in 2019, combined with the CSCO guidelines for diagnosis and treatment of neuroendocrine tumors (2021 Edition), type 1 g-nets were diagnosed: gastric neuroendocrine tumors (netg1 or netg2) with good differentiation were pathologically diagnosed. Serum gastrin was elevated, gastric parietal cell antibodies were positive, internal factor antibodies were positive, vitamin B12 was deficient, and gastroscopy showed multiple and polypoid lesions, Gastroscopy and pathology suggested (autoimmune) atrophic gastritis, HP (-), exclusion type 2 g-nets.
  • (3)Informed consent was signed.

排除标准

  • (1)Have a history of malignant tumors of other parts and types
  • (2)Have a history of gastric surgery
  • (3)Taking proton pump inhibitors and H2 receptor blockers for at least 3 months
  • (4)Combined with serious diseases that affect the evaluation of the study
  • (5)Participated in clinical research of other drugs within 3 months before participating in the project
  • (6)Patients in preparation for pregnancy
  • (7)Pregnant or lactating women.

研究者

发起方
China-Japan Friendship Hospital

相似试验